Drug Trial Radar · NCT06562894
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
Last checked: Nov 20, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
May 26, 2025
Primary completion
May 31, 2027
Study completion Nov 17, 2027
Sponsor
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- First posted
- Aug 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.
Conditions
- Severe Alopecia Areata
Interventions
SYHX1901Drug
Administered orally, once daily (QD)
PlaceboDrug
Administered orally, once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with Alopecia Severity Score Tool (SALT) score < or = 20%Time frame: Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.